Literature DB >> 18783940

Hormone replacement therapy and the risk of breast cancer.

Jack Cuzick1.   

Abstract

Hormone replacement therapy (HRT) has had a chequered history ever since its initial use to manage menopausal symptoms. It is clear that it has many other effects and here we review its impact on the risk of breast cancer. A clear risk is seen for current uses of combined oestrogen/progestagen pills, but this returns to normal shortly after treatment cessation. The role of oestrogen only replacement therapy is less clear, but most studies find a weaker, but still positive, association in current users. Recent sharp reductions in HRT use have been correlated with declines in breast cancer incidence in the USA, but not so clearly elsewhere.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783940     DOI: 10.1016/j.ejca.2008.07.041

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

1.  Cancer in women after assisted reproductive technology.

Authors:  Barbara Luke; Morton B Brown; Logan G Spector; Stacey A Missmer; Richard E Leach; Melanie Williams; Lori Koch; Yolanda Smith; Judy E Stern; G David Ball; Maria J Schymura
Journal:  Fertil Steril       Date:  2015-08-10       Impact factor: 7.329

2.  Breast Cancer and Socioeconomic Status in Austria.

Authors:  Ursula Kunze; Gabriela Böhm
Journal:  Breast Care (Basel)       Date:  2009-08-20       Impact factor: 2.860

3.  Estrogen receptor positive breast cancers and their association with environmental factors.

Authors:  Sophie St-Hilaire; Rakesh Mandal; Amy Commendador; Sylvio Mannel; DeWayne Derryberry
Journal:  Int J Health Geogr       Date:  2011-05-10       Impact factor: 3.918

4.  Behavioral risk factors and their relationship to tumor characteristics in Hispanic and non-Hispanic white long-term breast cancer survivors.

Authors:  Madiha F Abdel-Maksoud; Betsy C Risendal; Marty L Slattery; Anna R Giuliano; Kathy B Baumgartner; Tim E Byers
Journal:  Breast Cancer Res Treat       Date:  2011-08-06       Impact factor: 4.872

5.  Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis.

Authors:  Thomas P Ahern; Rulla M Tamimi; Bernard A Rosner; Susan E Hankinson
Journal:  Breast Cancer Res Treat       Date:  2014-02-28       Impact factor: 4.872

6.  Attributable causes of breast cancer and ovarian cancer in china: reproductive factors, oral contraceptives and hormone replacement therapy.

Authors:  Li Li; Jia Ji; Jian-Bing Wang; Mayineur Niyazi; You-Lin Qiao; Paolo Boffetta
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

7.  The effects of Tualang honey on female reproductive organs, tibia bone and hormonal profile in ovariectomised rats--animal model for menopause.

Authors:  Siti S M Zaid; Siti A Sulaiman; Kuttulebbai N M Sirajudeen; Nor H Othman
Journal:  BMC Complement Altern Med       Date:  2010-12-31       Impact factor: 3.659

8.  Expression of TGF-β1 in the blood during fracture repair in an estrogen-deficient rat model.

Authors:  Mohamed Abdalla Estai; Farihah Suhaimi; Srijit Das; Ahmad Nazrun Shuid; Zahiah Mohamed; Ima-Nirwana Soelaiman
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Spatial trends of breast and prostate cancers in the United States between 2000 and 2005.

Authors:  Rakesh Mandal; Sophie St-Hilaire; John G Kie; DeWayne Derryberry
Journal:  Int J Health Geogr       Date:  2009-09-29       Impact factor: 3.918

10.  Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study.

Authors:  Thomas P Ahern; Timothy L Lash; Henrik T Sørensen; Lars Pedersen
Journal:  Breast Cancer Res       Date:  2008-12-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.